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Abstract
Background: In high grade gliomas, 1p19q codeletion and EGFR amplification are mutually exclusive and
predictive of dramatically different outcomes. We performed a microarray gene expression study of four
high grade gliomas with 1p19q codeletion and nine with EGFR amplification, identified by CGH-array.
Results:  The two groups of gliomas exhibited very different gene expression profiles and were
consistently distinguished by unsupervised clustering analysis. One of the most striking differences was the
expression of normal brain genes by oligodendrogliomas with 1p19q codeletion. These gliomas harbored
a gene expression profile that partially resembled the gene expression of normal brain samples, whereas
gliomas with EGFR amplification expressed many genes in common with glioblastoma cancer stem cells.
The differences between the two types of gliomas and the expression of neuronal genes in gliomas with
1p19q codeletion were both validated in an independent series of 16 gliomas using real-time RT-PCR with
a set of 22 genes differentiating the two groups of gliomas (AKR1C3, ATOH8, BMP2, C20orf42, CCNB1,
CDK2, CHI3L1, CTTNBP2, DCX, EGFR, GALNT13, GBP1, IGFBP2, IQGAP1, L1CAM, NCAM1, NOG, OLIG2,
PDPN, PLAT, POSTN, RNF135). Immunohistochemical study of the most differentially expressed neuronal
gene, alpha-internexin, clearly differentiated the two groups of gliomas, with 1p19q codeletion gliomas
showing specific staining in tumor cells.
Conclusion: These findings provide evidence for neuronal differentiation in oligodendrogliomas with
1p19q codeletion and support the hypothesis that the cell of origin for gliomas with 1p19q codeletion
could be a bi-potential progenitor cell, able to give rise to both neurons and oligodendrocytes.
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Background
The 1p19q codeletion and EGFR amplification are mutu-
ally exclusive and related to dramatically different out-
comes in high grade gliomas. The 1p19q codeletion is
strongly associated with an oligodendroglial phenotype
and favorable prognosis [1]. It has recently been shown to
be mediated by a specific t(1;19)(q10;p10) translocation
[2]. To date the efforts performed to identify the genes
specifically involved in the breakpoint have failed, mostly
because both 1p and 19q centromeric regions contain
highly repeated sequences. As a consequence the molecu-
lar mechanisms underlying the particular phenotype and
the favorable outcome of this subset of gliomas remain
completely unknown. Reliable detection of 1p19q codele-
tion requires an appropriate technique, such as CGH-
array. Indeed, the most widely used LOH studies may not
distinguish this signature from partial distal 1p and 19q
deletion or gain, which have radically different prognostic
implications [1]. On the other hand, EGFR amplification
is tightly associated with chromosome 10 loss and gain of
chromosome 7, representing another characteristic
genomic signature [3]. EGFR amplification is more fre-
quent in glioblastomas, but it is also found in a subset of
anaplastic oligodendrogliomas and, in this setting, is pre-
dictive of extremely poor prognosis [4]. Recently, malig-
nant gliomas have been separated into three expression
profiles with distinct outcomes and histological correla-
tions: 1) the proneural profile with a better prognosis,
mostly corresponding to anaplastic gliomas (oligoden-
drogliomas and astrocytomas); 2) the proliferative and 3)
mesenchymal profiles, corresponding mainly to glioblas-
tomas [5]. However, correlation with 1p19q codeletion is
still missing. Based on a set of gliomas analyzed by CGH-
array [3], we selected tumors displaying one of these two
characteristics and mutually exclusive patterns -1p19q
codeletion or EGFR  amplification- and compared their
gene expression profiles.
Methods
Samples
The microarray study was done on 13 gliomas selected
from the Salpêtrière database, based on the following cri-
teria: 1) CGH-array profile showing either whole 1p19q
codeletion or EGFR amplification, 2) high quality RNA
availability. The samples were provided as snap-frozen
sections of areas immediately adjacent to the region used
for the histopathological diagnosis according to the
World Health Organization Classification (WHO 2000).
This set included 4 grade III oligodendrogliomas with
complete 1p19q codeletion and 9 gliomas with EGFR
amplification (5 glioblastomas (GBM), 3 grade III oli-
godendrogliomas, 1 grade III oligoastrocytoma (OAIII)).
Genomic characterization was performed using CGH
array as previously described [1]. Among the 9 tumors
with EGFR amplification, 8 out of 9 had chromosome 10q
loss and chromosome 7 gain; 4 had a gain of chromo-
some 1p, and 4 had a partial loss of chromosome 1p.
Among the 4 tumors with complete 1p19q codeletion
none had EGFR amplification, 10q loss or chromosome 7
gain, and 2 had complete chromosome 4 loss. In order to
compare the gene expression profile of the gliomas with
normal brain, we used the gene expression data of 5 sam-
ples of corpus callosum (GSM175855, GSM175856,
GSM175857, GSM175858, GSM176050) and 5 samples
of cortex (GSM176049, GSM176344, GSM176345,
GSM176346, GSM176347), available in the Gene Expres-
sion Omnibus repository (GSE7307) [6]. To compare the
gene expression profile with glioblastomas cancer stem
cells (CSC), we used the data of Beier et al. (GSE7181) [7].
All raw and normalized data files for the microarray anal-
ysis have been deposited [8] at the European Bioinformat-
ics Institute (Hinxton, UK), and are publicy available
under accession number E-MEXP-1507.
RNA extraction and hybridization
Approximately 50 mg of tissue from each tumor were used
for total RNA extraction using the RNeasy Lipid Tissue
mini kit (Qiagen, CA), according to the manufacturer
instructions. RNA quality was verified with the Bioana-
lyser System (Agilent Technologies, Paolo Alto, CA), using
the RNA Nano Chips. One and half micrograms of RNA
were processed for hybridization on the Genechip Human
Genome U133 Plus 2.0 Expression array (Affymetrix, CA),
which contains over 54.000 probe sets analyzing the
expression level of over 47,000 transcripts and variants,
including 38.500 well-characterized human genes. The
processing was done according to the recommendations
of the manufacturer.
Data analysis
Except as indicated, all transcriptome analysis was carried
out using either R-system software (version 2.4.1) pack-
ages including those of Bioconductor [9]or original R
code (A. de R.). Normalization was performed using the
RMA method [10]. Clustering analysis was performed as
previously reported [11]. Class comparison using a uni-
variate t-test was performed using BRB Array Tools devel-
oped by Dr. Richard Simon and Amy Peng Lam [12]. A p-
value < 0.001 was used to define differentially expressed
genes. Gene set enrichment analysis was performed using
GSEA v2.0 software [13] as described by Subramanian et
al. [14]. For enrichment analysis in specific gene ontology
terms (GO terms), we used a hypergeometric test to meas-
ure the association between a gene (probe set) list and a
GO term. To this end, we mapped both the gene list and
GO term related proteins to non-redundant Entrez Gene
identifiers. The mapping of a probe set list to Entrez Gene
ids was done using the annotation file HG-
U133_Plus_2.annot.csv [15]. For each GO term, we
obtained the list of non-redundant related protein identi-Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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fiers – either directly associated with the GO term or with
one of its descendants – and mapped it to a non-redun-
dant list of Entrez Gene ids. GO terms and their relation-
ships (parent/child) were downloaded from The Gene
Ontology site [16]. The list of proteins associated with GO
terms (table gene_association.goa_human) was down-
loaded from [17]. We designated a threshold significance
level for the hypergeometric test of p < 0.01 and the crite-
ria that a GO term was represented by at least 2 Entrez
Gene identifiers. Enrichment analysis of genes located on
specific chromosomes was performed using DAVID tools
[18].
Real-time RT-PCR
Quantitative RT-PCR was performed as previously
described [19]. TBP  (Genbank accession no.
NM_003194), which encodes the TATA box-binding pro-
tein (a component of the DNA-binding protein complex
transcription factor II D), was selected as an endogenous
control because the levels of its transcript did not change
across various normal tissues and tumor samples. The
expression of the following 22 genes was quantified:
AKR1C3 (upper primer (UP) 5'-CGT ATT TCA ACC GGA
GTA AAT TGC TA-3', lower primer (LP) 5'-GTT CGG GTC
CAC CCA TCG T-3'); ATOH8 (UP 5'-CAC ACC ATC AGC
GCA GCC TT-3', LP 5'-GAT GGC CAG TTT GGA CAG CTT
CT-3'); BMP2 (UP 5'-CGC AGC TTC CAC CAT GAA GAA
TC-3', LP 5'-GAA TCT CCG GGT TGT TTT CCC ACT-3');
C20orf42 (UP 5'-AAG GAA CTT GAA CAA GGA GAA CCA
CT-3', LP 5'-GGC ACA ACT TCG CAG CCT CTA-3');
CCNB1 (UP 5'-TGG ATA ATG GTG AAT GGA CAC CAA-
3', LP 5'-GCC AGG TGC TGC ATA ACT GGA-3'); CDK2
(UP 5'-GGA CGG AGC TTG TTA TCG CAA AT-3', LP 5'-
CCT TGG CCG AAA TCC GCT T-3'); CHI3L1 (UP 5'-GAC
CAC AGG CCA TCA CAG TCC-3', LP 5'-TGT ACC CCA
CAG CAT AGT CAG TGT T-3'); CTTNBP2 (UP 5'-CCC TCT
CCA TCC TTG AAG CAG T-3', LP 5'-GAA GCT TCT CCA
TTT CCA GCT TCT-3'); DCX (UP 5'-AGC CAA GAG CCC
TGG TCC TAT-3', LP 5'-TGG AGG TTC CGT TTG CTG
AGT-3');EGFR (UP 5'-GGA GAA CTG CCA GAA ACT GAC
C-3', LP 5'-GCC TGC AGC ACA CTG GTT G-3');GALNT13
(UP 5'-GTG GCC TAT TTT CTA TTG ACA GAA ACT-3', LP
5'-CCT CCA CAT TGC CAA ATC CTA A-3');GBP1 (UP 5'-
CCT CGC TCT TAA ACT TCA GGA ACA-3', LP 5'-CCT TTC
GTC GTC TCA TTT TCG T-3');IGFBP2 (UP 5'-GGC CCT
CTG GAG CAC CTC TAC T-3', LP 5'-CCG TTC AGA GAC
ATC TTG CAC TGT-3');IQGAP1 (UP 5'-AGA ACA GAC
CAG ATA CAA GGC GA-3', LP 5'-CTT AGG CAA TCC AAT
CTC ATC CA-3');L1CAM (UP 5'-CTG GTT GTC TTC CCC
ACA GAT GA-3', LP 5'-TCG TCC AGC GGA ACT GCA CT-
3');NCAM1 (UP 5'-CCA CAG CCA TCC CAG CCA A-3', LP
5'-GAC GAT GAG GAT GCC CAC GAT-3');NOG (UP 5'-
AAG AAG CAG CGC CTA AGC AAG A-3', LP 5'-GTC GTT
CCA CGC GTA CAG CA-3');OLIG2 (UP 5'-CGC CAG AGC
CCG ATG ACC TT-3', LP 5'-GAC ACG GTG CCC CCA
GTG AA-3');PDPN (UP 5'-GTG ACT CCA GGA ACC AGC
GAA-3', LP 5'-TGA CAC TTG TTG CCA CCA GAG TT-
3');PLAT (UP 5'-AGC AGG CCC TGT ACT TCT CAG ATT-
3', LP 5'-ACG TGG CCC TGG TAT CTA TTT CA-3');POSTN
(UP 5'-GTC CTA ATT CCT GAT TCT GCC AAA-3', LP 5'-
GGG CCA CAA GAT CCG TGA A-3');RNF135 (UP 5'-TGC
CTG ACC AGA GCC ACC C-3', LP 5'-GAT GGA TGG CCC
ACT GAG CA-3'); TBP (UP 5'-TGC ACA GGA GCC AAG
AGT GAA-3', LP 5'-CAC ATC ACA GCT CCC CAC CA-3').
RT-PCR validation was done in an independent set of 16
gliomas (8 grade III oligodendrogliomas with complete
1p19q codeletion and 8 glioblastomas with EGFR ampli-
fication) and on 3 samples of normal brain (temporal
lobe obtained during surgery for epilepsy).
Immunohistochemistry
Immunohistochemical analyses were carried out on paraf-
fin sections using antibodies directed against internexin
neuronal intermediate filament protein alpha (INA) [20].
Immunostaining was studied in five glioblastomas with
EGFR amplification and five anaplastic oligodendroglio-
mas with complete 1p19q codeletion.
Results
Transcriptomic differences partly reflect the underlying 
genomic alterations
To study the relationship between the differences in gene
expression profile and the underlying genomic altera-
tions, we looked at the genomic localization of the differ-
entially expressed genes. Class comparison using a
univariate t-test demonstrated that 4458 probe sets were
differentially expressed between the two groups of glio-
mas with a p-value < 0.001 and a maximum false discov-
ery rate of 1.2% (see Additional file 1). The set of
overexpressed genes in gliomas with EGFR amplification
was significantly enriched in genes located on chromo-
some 1 (305 genes, p < 10-4), chromosome 19 (151 genes,
p < 10-4), chromosome 7 (109 genes, p < 10-4) and chro-
mosome 4 (85 genes, p < 10-4). In contrast, the set of over-
expressed genes in gliomas with 1p19q codeletion was
significantly enriched in genes located on chromosome
10 (216 genes, p < 10-4). Thus, gene expression and copy
number variation dynamics were tightly correlated in
both tumor groups. This was even more obvious when we
plotted the differentially expressed probe sets localized on
chromosome 1, 19 and 10 according to their genomic
localization and the log2 ratio of their geometric mean in
both tumor groups (Figure 1). Indeed, almost all differen-
tially expressed genes localized on 1p and 19q were
underexpressed in gliomas with 1p19q codeletion,
whereas differentially expressed genes localized to 1q and
19p were equally distributed (Figure 1).Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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Genomic localization of the differentially expressed probe sets (p < 0 Figure 1
Genomic localization of the differentially expressed probe sets (p < 0.001) localized on chromosome 1, 19 and 
10. Each probe set is represented by a dot. Probe sets are ordered along the x axis according to their genomic position (only 
probe sets with unambiguous genomic mapping on UCSC were used). For each chromosome, the telomere of the short arm is 
on the left, and the telomere of the long arm is on the right. The dashed vertical line represents the position of the centro-
mere. The y axis corresponds to the log2 ratio of the geometric mean in the gliomas with complete 1p19q loss versus the gli-
omas with EGFR amplification. Almost all probe sets localized on 1p and 19q were underexpressed in gliomas with 1p19q 
codeletion, whereas most of the probe sets localized on chromosome 10 were overexpressed.Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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Unsupervised analysis consistently distinguishes the two 
groups of gliomas
In order to study the differences in gene expression pro-
file, we performed unsupervised hierarchical clustering
analysis of the 13 glioma samples. This analysis was done
using the 1366 probe sets whose expression varied the
most across samples (this corresponds to the probe sets
with a robust coefficient of variation (rCV) superior to the
97.5th rCV percentile). As shown in Figure 2, gliomas with
1p19q codeletion and gliomas with EGFR amplification
segregated into two distinct groups. This clustering was
extremely robust and was conserved across different gene
Unsupervised clustering of 4 oligodendrogliomas with 1p19q codeletion and 9 gliomas with EGFR amplification Figure 2
Unsupervised clustering of 4 oligodendrogliomas with 1p19q codeletion and 9 gliomas with EGFR amplification. 
Unsupervised hierarchical clustering was performed using the 1366 probe sets whose expression varied the most across the 
13 samples (probe sets with a robust coefficient of variation superior to the 97.5th percentile). Samples and genes were clus-
tered using Ward's linkage and 1-Pearson correlation coefficient. For each probe set, data were median-centered (white), with 
the lowest and highest intensity values in blue and red, respectively. 1p19q = 1p19q codeletion, EGFR = EGFR amplification. The 
gliomas were classified into 2 groups according to their genomic profile. Gliomas with EGFR amplification were classified into 
one cluster irrespective of their histology (red = glioblastoma, green = grade III oligodendroglioma, blue = grade III oligoastro-
cytoma). Gene cluster A was enriched in genes involved in proliferation, extracellular matrix, immune response, embryonic 
development and angiogenesis. Gene cluster B was enriched in genes involved in synaptic transmission. Gene cluster C was 
enriched in genes involved in neurogenesis and synaptic transmission.Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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lists and clustering methods. The genes were classified
into three clusters: one cluster of genes overexpressed in
gliomas with EGFR  amplification (gene cluster A, 698
genes), one cluster of genes overexpressed in oligodendro-
gliomas with 1p19q codeletion (gene cluster C, 488
genes) and a smaller cluster of genes expressed by some
samples of both groups (gene cluster B, 180 genes).
Enrichment analysis was performed on these three gene
clusters. First, chromosome enrichment analysis demon-
strated that these gene clusters did not simply reflect the
underlying genomic alterations. Indeed, gene cluster A
was enriched in genes located on chromosome 4 (53
genes, p < 10-4) and on chromosome 7 (43 genes, p < 10-
2), but not in genes located on chromosome 1 or chromo-
some 19. Neither gene cluster C nor gene cluster B was
enriched in genes located on chromosome 10. In contrast,
the three gene clusters were enriched in genes with specific
ontologic classes. Gene cluster A was most significantly
enriched in genes involved in: immune response (55
genes, p < 10-4), extracellular matrix (37 genes, p < 10-4),
proliferation (45 genes, p < 10-4), blood vessel develop-
ment (17 genes, p < 10-4) and embryonic development
(14 genes, p < 10-4). This cluster contained several genes
well-known to be overexpressed in glioblastomas
(IGFBP2, CHI3L1) and markers of glioblastoma cancer
stem cells as well (CD133, IQGAP1). In contrast, gene
cluster C was significantly enriched in genes with different
specific ontologic classes: nervous system development
(42 genes, p < 10-4), synaptic transmission (26 genes, p <
10-4) and neurogenesis (13 genes, p < 10-4). Actually,
most of the genes in gene cluster C were either related to
neuronal function or neuronal development or known to
be highly expressed in normal brain. Gene cluster B was
also enriched in genes involved in synaptic transmission
(17 genes, p < 10-4) and nervous system development (16
genes, p < 10-4). However, two ontologic classes specifi-
cally found in this cluster (neurofilament (3 genes, p < 10-
4) and axon ensheathment (2 genes, p < 10-2)) suggested
that this cluster contained genes expressed in more differ-
entiated neural cells than gene cluster C.
Oligodendrogliomas with 1p19q codeletion express 
specific subsets of neuronal genes
In order to better characterize the expression of neuronal
genes in gliomas with complete 1p19q codeletion, we per-
formed a new hierarchical clustering analysis with sam-
ples of normal brain (GSE7307), including grey matter
(cortex) and white matter (corpus callosum). As glioblas-
tomas expressed genes of neural cancer stem cells, we also
included samples of glioblastoma cancer stem cells
(GSE7181) [7] in this analysis. Still using the most differ-
entially expressed 1366 probe sets, the samples clustered
into two major groups: one containing 1p19q codeleted
gliomas, normal white matter and normal grey matter,
and the other containing EGFR  amplified gliomas and
cancer stem cells (Figure 3). Again this clustering was
found to be extremely robust and was conserved across
different gene lists and clustering methods. Gene ontol-
ogy enrichment analysis was performed on the main gene
clusters (A to J). Despite the clustering of 1p19q codeleted
gliomas with normal brain, they showed substantial dif-
ferences. First, the genes characteristics of the corpus cal-
losum (gene cluster A), enriched in myelination genes (5
genes, p < 10-4), were not overexpressed in gliomas with
1p19q codeletion. Second, gliomas with 1p19q only over-
expressed one subset of the neuronal genes characteristic
of the cortex samples (gene clusters B and C). For exam-
ple, among the neurofilament genes (INA, NEFH, NEFM,
NEFL) present in cluster C, alphainternexin (INA) was the
only one overexpressed in both gliomas with 1p19q code-
letion and cortex samples in comparison to gliomas with
EGFR amplification. Third, 1p19q codeleted gliomas were
characterized by one specific cluster (gene cluster D)
enriched in genes involved in CNS development (6 genes,
p < 10-4), which also contained genes known to be specif-
ically expressed in neuronal cells in the physiological
state, e.g. DCX and GALNT1 [21,22]. Thus, gliomas with
1p19q codeletion had a specific gene expression pattern
of neuronal genes different from the samples of normal
brain. Gliomas with EGFR amplification and glioblast-
oma cancer stem cells were both characterized by a large
gene cluster (G) most significantly enriched in genes
involved in proliferation (34 genes, p < 10-4) and in CNS
development (16 genes, p < 10-4). Gliomas with EGFR
amplification segregated from the cancer stem cells by one
main gene cluster (I) enriched in genes involved in
immune response (11 genes, p < 10-4), extracellular
matrix (7 genes, p < 10-4) and angiogenesis (4 genes, p <
10-4).
Most characteristic genes associated with 
oligodendrogliomas with 1p19q codeletion
To find the genes most specifically associated with oli-
godendrogliomas with 1p19q codeletion, we selected the
probe sets that were consistently (> 2-fold) and signifi-
cantly (t test p < 0.001) overexpressed in these gliomas
when they were independently compared to each of the 4
other samples groups (i.e., gliomas with EGFR amplifica-
tion, cortex samples, corpus callosum samples and gliob-
lastoma cancer stem cells). Eighty-six probe sets
corresponding to 39 well-annotated genes met these crite-
ria (Table 1 and see additional file 1). Several genes on
this list are known to be highly expressed in normal brain
(CSMD3, C20orf42, CTTNBP2), and one is known to be
specifically expressed by neuronal cells (GALNT13) [22].
Two transcription factors that play a role in CNS develop-
ment were also specifically overexpressed (ATOH8,
NFIB).  ATOH8  is a basic-helix-loop-helix transcription
factor, whose homolog in mouse has been demonstrated
to regulate neuronal versus glial fate [23]. NFIB plays aMolecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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role in brain development, and Nfib deficient mice exhibit
callosal agenesis [24]. Finally, an intriguing feature was
the specific overexpression of both BMP2, which pro-
motes astroglial differentiation, and its antagonist NOG,
which has been shown to promote both neuronal and oli-
godendroglial differentiation [25-27].
Oligodendrogliomas with 1p19q have a proneural gene 
expression profile
As gliomas with 1p19q codeletion expressed neuronal
genes, we performed gene set enrichment analysis (GSEA)
to study the relationship between the gene expression pro-
file of these gliomas and the "proneural" gene expression
signatures that have been described in high grade gliomas
Unsupervised clustering of 4 gliomas with 1p19q codeletion, 9 gliomas with EGFR amplification, 6 glioblastoma cancer stem  cells cell lines and 10 normal brain tissue samples Figure 3
Unsupervised clustering of 4 gliomas with 1p19q codeletion, 9 gliomas with EGFR amplification, 6 glioblastoma 
cancer stem cells cell lines and 10 normal brain tissue samples. Unsupervised hierarchical clustering was performed 
using the 1366 probe sets whose expression varied the most across the 29 samples (probe sets with a robust coefficient of 
variation superior to the 97.5th percentile). Samples and genes were clustered using Ward's linkage and 1-Pearson correlation 
coefficient. For each probe set, data were median-centered (white), with the lowest and highest intensity values in blue and 
red, respectively. 1p19q = 1p19q codeletion, EGFR = EGFR amplification, CC = corpus callosum, Cx = cortex, CSC = cancer 
stem cells. The 29 gliomas were classified into 2 groups and 5 subgroups. Gliomas with EGFR amplification were classified with 
the cancer stem cell lines. Gliomas with 1p19q codeletion were classified with the normal brain samples, however their gene 
expression pattern was clearly different from the gene expression pattern of the white matter (corpus callosum) and grey mat-
ter (cortex) samples.Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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Table 1: Most characteristic genes associated with oligodendrogliomas with 1p19q codeletion
Probe set Title Gene Symbol Gene ontology 
(biological 
process)
High expression 
in:
FD/EGFR FD/Cx FD/CC FD/Stem cells
206785_s_at Killer cell lectin-like 
receptor subfamily 
C, member 1///
member 2
KLRC1//KLRC2 Cellular defense 
response
Natural killer cells 104.2 92.1 61.4 66.7
243779_at, 
236536_at
UDP-N-acetyl-alpha-
D-
galactosamine:polype
ptide N-
acetylgalactosaminylt
ransferase 13 
(GalNAc-T13)
GALNT13 Protein amino acid 
O-linked 
glycosylation
Specifically 
expressed in 
neuronal cells
31.8 18.2 17.1 15.0
1558706_a_at, 
228890_at
Atonal homolog 8 
(Drosophila)
ATOH8 Regulation of 
transcription
--- 26.1 30.8 21.4 27.1
240228_at CUB and Sushi 
multiple domains 3
CSMD3 Integral to 
membrane
Brain 22.7 11.8 13.9 15.1
207723_s_at Killer cell lectin-like 
receptor subfamily 
C, member 3
KLRC3 Cellular defense 
response
Natural killer cells 17.9 27.3 13.1 11.3
230826_at Monocyte to 
macrophage 
differentiation-
associated 2
MMD2 Cytolysis --- 17.2 7.2 9.1 26.2
60474_at, 
218796_at
Chromosome 20 
open reading frame 
42
C20orf42 Cell adhesion Brain (among 
others)
16.2 37.4 29.1 19.6
231798_at Noggin NOG Nervous system 
development
--- 11.2 9.2 9.5 13.6
1556599_s_at Cyclic AMP-
regulated 
phosphoprotein, 21 
kD
ARPP-21 --- --- 11.1 14.0 16.8 13.9
227845_s_at Src homology 2 
domain containing 
transforming protein 
D
SHD Intracellular 
signaling cascade
--- 10.3 10.6 16.5 7.6
205289_at, 
205290_s_at
Bone morphogenetic 
protein 2
BMP2 Positive regulation 
of astrocyte 
differentiation
Brain (among 
others)
10.1 30.7 25.9 12.7
205330_at Meningioma 
(disrupted in 
balanced 
translocation) 1
MN1 Negative regulation 
of progression 
through cell cycle
Ubiquitously 
expressed
8.4 5.8 9.5 15.9
219668_at Ganglioside-induced 
differentiation-
associated protein 1-
like 1
GDAP1L1 --- --- 8.4 4.2 9.1 7.9
204530_s_at Thymus high 
mobility group box 
protein TOX
TOX Regulation of 
transcription
--- 8.3 6.6 12.5 6.0
228790_at, 
221959_at
Chromosome 8 
open reading frame 
72
C8orf72 --- --- 7.6 14.6 19.1 36.6
232136_s_at Cortactin binding 
protein 2
CTTNBP2 --- Brain 5.4 7.1 4.3 6.5
233136_at Poly(A) binding 
protein, cytoplasmic 
5
PABPC5 --- Fetal brain 5.4 4.6 4.6 4.9
219093_at Phosphotyrosine 
interaction domain 
containing 1
PID1 --- Brain (among 
others)
5.1 12.3 23.0 4.0
205773_at Cytoplasmic 
polyadenylation 
element binding 
protein 3
CPEB3 Nucleotide binding --- 4.5 4.0 4.8 5.4
1560265_at Glutamate receptor, 
ionotropic, kainate 2
GRIK2 Regulation of 
synaptic 
transmission
Cerebellum, 
cerebral cortex
4.5 3.7 5.9 7.1
238526_at RAB3A interacting 
protein (rabin3)
RAB3IP protein transport Brain (among 
others)
4.4 5.9 7.2 3.2
213001_at, 
219514_at
Angiopoietin-like 2 ANGPTL2 Development Heart among 
others
3.9 12.2 6.0 4.0
229590_at Ribosomal protein 
L13
RPL13 Translation --- 3.8 3.7 3.8 2.8
206117_at Tropomyosin 1 
(alpha)
TPM1 Cell motility Muscle among 
others
3.6 4.1 4.2 3.3
202315_s_at, 
217223_s_at
Breakpoint cluster 
region
BCR Regulation of Rho 
protein signal 
transduction
--- 3.3 4.4 7.6 4.5Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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234268_at Solute carrier family 
2 (facilitated glucose 
transporter), 
member 13
SLC2A13 Carbohydrate 
transport
Brain 3.1 3.4 4.1 3.2
228813_at, 
204225_at
Histone deacetylase 
4
HDAC4 Nervous system 
development
Ubiquitously 
expressed
3.1 2.6 3.9 4.4
209511_at Polymerase (RNA) II 
(DNA directed) 
polypeptide F
POLR2F Regulation of 
transcription
--- 3.0 6.9 4.7 3.0
213033_s_at, 
213032_at
Nuclear factor I/B NFIB Regulation of 
transcription, DNA-
dependent, Brain 
development
--- 3.0 10.7 13.8 8.2
204100_at Thyroid hormone 
receptor, alpha 
(erythroblastic 
leukemia viral (v-erb-
a) oncogene 
homolog, avian)
THRA Negative regulation 
of transcription
Brain (among 
others)
2.9 2.9 2.2 3.7
230198_at WD repeat domain 
37
WDR37 --- --- 2.8 4.0 2.8 2.6
213758_at Cytochrome c 
oxidase subunit IV 
isoform 1
COX4I1 Electron transport Ubiquitously 
expressed
2.4 2.2 2.7 3.2
221012_s_at Tripartite motif-
containing 8///
tripartite motif-
containing 8
TRIM8 --- Brain (among 
others)
2.3 3.1 3.2 3.2
202182_at GCN5 general 
control of amino-
acid synthesis 5-like 
2 (yeast)
GCN5L2 Regulation of 
transcription, DNA-
dependent
Ubiquitously 
expressed
2.3 2.5 2.4 2.3
214198_s_at DiGeorge syndrome 
critical region gene 2
DGCR2 Cell adhesion Brain (among 
others)
2.3 3.4 5.0 2.4
225334_at Chromosome 10 
open reading frame 
32
C10orf32 --- --- 2.2 3.5 4.1 3.2
210690_at Killer cell lectin-like 
receptor subfamily 
C, member 4
KLRC4 Cellular defense 
response
Natural killer cells 2.2 2.2 2.0 2.2
203938_s_at TATA box binding 
protein (TBP)-
associated factor, 
RNA polymerase I, 
C, 110kDa
TAF1C Transcription --- 2.1 3.2 2.6 2.1
217969_at Chromosome 11 
open reading frame2
C11orf2 --- --- 2.0 2.8 3.9 3.3
39 well-characterized genes were significantly upregulated (FC > 2 and p < 0.001) in oligodendrogliomas with 1p19q codeletion in comparison to 
each of the 4 other sample groups. Underlined genes were studied and validated by real-time RT-PCR in the independent sample set. FD/EGFR = 
Fold difference of geometric means (FD) in gliomas with 1p19q codeletion in comparison to gliomas with EGFR amplification, FD/Cx = FD in 
gliomas with 1p19q codeletion in comparison to cortex samples, FD/CC = FD in gliomas with 1p19q codeletion in comparison to corpus callosum, 
FD/Stem cells = FD in gliomas with 1p19q codeletion in comparison to glioblastomas cancer stem cells [7]. 
Table 1: Most characteristic genes associated with oligodendrogliomas with 1p19q codeletion (Continued)
with a good prognosis (Figure 4) [5,14,28]. This test deter-
mines the over-representation of a gene set (list of genes)
at the extremes (top or bottom) of the ordered, non-
redundant dataset (list of all of the genes being used to
compare two groups of samples). This analysis demon-
strated that gliomas with 1p19q codeletion in comparison
to gliomas with EGFR  amplification were significantly
enriched in the "proneural" gene set associated with good
prognosis reported by Phillips et al. and in the good prog-
nosis neurogenesis-related gene set reported by Freije et al.
(HC1A gene set) [5,28]. They were also enriched in the
HC1B gene set (neuronal genes) of Freije et al. In contrast,
gliomas with EGFR amplification were enriched in gene
sets associated with poor prognosis ("proliferation" and
"mesenchymal" gene sets of Phillips et al., and HC2A
(enriched in proliferation genes) and HC2B (enriched in
extracellular matrix genes) gene sets of Freije et al.) [5,28].
Next we used the 35 genes signature developed by Phillips
et al. to distinguish the three groups of high grade gliomas
(proneural, proliferative and mesenchymal) in order to
perform unsupervised hierarchical clustering [5]. As
shown in Figure 5, the gliomas with 1p19q codeletion
were classified as proneural. Thus, there was a clear asso-
ciation between the "proneural" gene expression profile
and 1p19q codeletion.
Real-time RT-PCR validation
To validate these findings, we studied the expression of 22
selected genes differentially expressed (11 up and 11
down) between the two groups of gliomas in an inde-
pendent data set of 16 gliomas (8 gliomas with EGFR
amplification and 8 gliomas with 1p19q codeletion). This
study was performed in comparison with 3 samples of
normal brain obtained from epileptic surgery (Table 2,Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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GSEA Enrichment Score curves Figure 4
GSEA Enrichment Score curves. Gene set enrichment analysis (GSEA) was performed with 6 different gene sets obtained 
from the studies of Phillips et al. and Freije et al. Phillips' study gene sets: A: Proneural gene set (n = 220 genes), B: Proliferative 
gene set (n = 148 genes), C: Mesenchymal gene set (n = 126 genes). Freije's study gene sets: D: HC1A neurogenesis related 
gene set (n = 73), E: HC2A proliferation related gene set (n = 66 genes), F: HC2B extracellular matrix related gene set (n = 239 
genes) [5, 28]. "Signal-to-Noise" ratio (SNR) statistic was used to rank the genes according to their correlation with either the 
1p19q codeletion phenotype (red) or EGFR amplification phenotype (blue). The graph on the bottom of each panel represents 
the ranked, ordered, non-redundant list of genes. Genes on the far left (red) correlated the most with 1p19q codeleted sam-
ples, and genes on the far right (blue) correlated the most with EGFR amplified samples. On each panel, the vertical black lines 
indicate the position of each of the genes of the studied gene set in the ordered, non-redundant data set. The green curve cor-
responds to the ES (enrichment score) curve, which is the running sum of the weighted enrichment score obtained from GSEA 
software. A and D show that gliomas with 1p19q codeletion were significantly enriched in the proneural and neurogenesis 
related (HC1A) gene sets. B, C, D and E show that gliomas with EGFR amplification were significantly enriched in the prolifera-
tion/HC2A and mesenchymal/HC2B gene sets.Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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Figure 6 and see additional file 2). Using a univariate t-
test, 21 out of the 22 genes studied were shown to be dif-
ferentially expressed between the two groups of gliomas
with a p-value < 0.05 (only NCAM1 was not validated).
This confirmed that gliomas with 1p19q codeletion over-
expressed neuronal/normal brain genes (AKR1C3,
C20orf42, CTTNBP2, L1CAM, GALNT13) as well as genes
implicated in gliogenesis and neurogenesis (OLIG2,
BMP2, NOG, DCX, ATOH8). Except L1CAM and AKR1C3,
all of these genes were also overexpressed in comparison
to the normal brain samples, including two genes (DCX,
GALNT13) known to be exclusively expressed in neuronal
cells.  BMP2, NOG, C20orf42, GALNT13 and  OLIG2
Unsupervised clustering of the 4 gliomas with 1p19q codeletion and the 9 gliomas with EGFR amplification using 35 genes signa- ture of Phillips et al. [5] Figure 5
Unsupervised clustering of the 4 gliomas with 1p19q codeletion and the 9 gliomas with EGFR amplification 
using 35 genes signature of Phillips et al. [5]. Samples and genes were clustered using Ward's linkage and 1-Pearson cor-
relation coefficient. 1p19q = gliomas with 1p19q codeletion, EGFR = gliomas with EGFR amplification. Gliomas with 1p19q 
codeletion were classified as proneural, whereas gliomas with EGFR amplification had both a mesenchymal and proliferative 
profile. In red are the genes whose expression was studied in real-time RT-PCR in an independent data set.Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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belong to the list of proneural genes reported by Phillips
[5].
In the gliomas with EGFR amplification, we confirmed
the overexpression of genes implicated in proliferation
(CCNB1, CDK2), extracellular matrix remodeling (PLAT,
POSTN), immune response (GBP1), cancer stem cell sig-
naling (IQGAP1) as well as several genes known to be
highly expressed in glioblastomas (IGFBP2, CHI3L1,
PDPN). CCNB1, CDK2 belong to the proliferative gene
list, and CHI3L1 and PDPN, to the mesenchymal gene list
of Phillips [5].
Alpha-internexin immunohistochemistry
Finally, to validate the expression of neuronal genes in gli-
omas with 1p19q codeletion at the protein level, we stud-
ied the expression of the internexin neuronal intermediate
filament protein alpha (INA) which was one of the neuro-
nal genes most overexpressed in these gliomas in compar-
ison to gliomas with EGFR amplification (FC = 15, p <
0.001). INA is a class-IV neuronal intermediate filament
Table 2: Real-time RT-PCR study of 22 differentially expressed genes
Gene symbol Description Gene ontology Fold difference of geom 
means 1p19q/EGFR 
(microarray)*
Fold difference of geom 
means 1p19q/EGFR in 
validation sample set (RT-
PCR)**
AKR1C3 Aldo-keto reductase family 1, 
member C3
Prostaglandin 
metabolism
17.5 7.1
ATOH8 Atonal homolog 8 (Drosophila) Regulation of 
transcription
26 23.5
BMP2 Bone morphogenetic protein 2 Positive regulation of 
astrocyte differentiation
10.1 10.2
C20ORF42 Chromosome 20 open reading 
frame 42
Cell adhesion 16.2 15.7
CTTNBP2 Cortactin binding protein 2 --- 5.4 3.9
DCX Doublecortex; lissencephaly, X-
linked (doublecortin)
CNS development 5.9 6.3
GALNT13 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 13 
(GalNAc-T13)
Protein amino acid O-
linked glycosylation
31.7 38.4
L1CAM L1 cell adhesion molecule Nervous system 
development
14.6 24.5
NCAM1 Neural cell adhesion molecule 1 Synaptic transmission 4.8 1.7(NS)
NOG Noggin Nervous system 
development
11.2 18.4
OLIG2 Oligodendrocyte lineage 
transcription factor 2
Nervous system 
development
4.7 3.7
CCNB1 Cyclin B1 Mitosis 0.2 0.2
CDK2 Cyclin-dependent kinase 2 Mitosis 0.2 0.2
CHI3L1 Chitinase 3-like 1 (cartilage 
glycoprotein-39)
Chitin catabolism 0.01 0.003
EGFR Epidermal growth factor receptor 
(erythroblastic leukemia viral (v-
erb-b) oncogene homolog, avian)
Cell proliferation 0.1 0.2
GBP1 Guanylate binding protein 1, 
interferon-inducible, 67kDa
Immune response 0.05 0.05
IGFBP2 Insulin-like growth factor binding 
protein 2, 36 kDa
Regulation of cell 
growth
0.02 0.01
IQGAP1 IQ motif containing GTPase 
activating protein 1
Signal transduction 0.11 0.1
PDPN Podoplanin Positive regulation of 
cell motility
0.02 0.008
PLAT Plasminogen activator, tissue Proteolysis 0.07 0.06
POSTN Periostin, osteoblast specific factor Cell adhesion 0.01 0.01
RNF135 Ring finger protein 135 --- 0.2 0.2
Fold difference of geometrical means in microarray and in real-time RT-PCR of the 22 genes studied in the independent sample set. * All genes 
were differentially expressed with a p-value < 0.001 except DCX (p-value = 0.004). * * All genes were differentially expressed with a p-value < 0.05 
except when NS (non significant) is specified.Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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Real-time RT PCR study of 22 genes differentially expressed between 1p19q codeleted gliomas and EGFR amplified gliomas Figure 6
Real-time RT PCR study of 22 genes differentially expressed between 1p19q codeleted gliomas and EGFR 
amplified gliomas. Real-time RT-PCR study of 11 genes overexpressed in gliomas with EGFR amplification (top) and 11 genes 
overexpressed in gliomas with 1p19q codeletion (bottom) was performed in an independent data set of 16 gliomas (8 gliomas 
with EGFR amplification (triangles), 8 gliomas with 1p19q codeletion (circles)). Each dot represents the relative expression 
(log2 transformed) of a given gene in one glioma compared with normal brain (median expression in the 3 normal brain sam-
ples). Dots above the upper dashed line are upregulated with a fold change larger than 2 in comparison to normal brain; dots 
below the lower dashed line are downregulated in comparison to normal brain with a fold change larger than 2. For example, 
NOG, BMP2 and ATOH8 were overexpressed in all 8 gliomas with 1p19q codeletion (circles) in comparison to all 8 gliomas with 
EGFR amplification (triangles) and in comparison to normal brain. CHI3L1, PLAT, IQGAP1, IGFFBP2 and GBP1were overexpressed 
in all gliomas with EGFR amplification (triangles) in comparison to gliomas with 1p19q codeletion (circles) and in comparison to 
normal brain. Except for NCAM1, all 22 genes were differentially expressed (p < 0.05).Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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involved in the morphogenesis of neurons [29]. Immu-
nostaining for INA was positive in all five oligodendrogli-
omas with 1p19q codeletion examined.
Immunopositivity was observed in some normal infil-
trated neurons but was mostly seen in a specific cytoplas-
mic perinuclear staining pattern in tumor cells (Figure 7).
Between 20 to 50% of tumor cells displayed this staining,
which was different from the staining observed in the
infiltrated normal neurons (Figure 7). Among the five
glioblastomas with EGFR amplification, immunostaining
was negative in four and positive in a scattered pattern in
one, in a region displaying some features of oligodendro-
glial differentiation.
Discussion
EGFR  amplification and whole 1p19q codeletion are
mutually exclusive and predictive of completely different
outcomes [3,4]. To date, no studies have compared the
gene expression profile of these two types of gliomas.
Indeed, among microarray studies of gliomas
[5,28,30,31], only a few have compared genetically well-
defined tumors [32-35]. In addition, these studies were
based on LOH or FISH [32-34], and not on CGH-array.
Yet, there is a need when interpreting a difference in gene
expression to analyze it in relation to the genomic profile.
Our data reveals clearly distinct gene expression profiles
in these 2 groups of gliomas: those with EGFR amplifica-
tion express the proliferative and mesenchymal gene set
defined by Phillips et al., while 1p19q codeleted gliomas
express the proneural group [5]. Moreover, gliomas with
EGFR amplification clustered close to tumor stem cells.
Indeed, the EGFR pathway is involved in the proliferation
of normal neural stem cells and cancer stem cells [36].
This result is consistent with the fact that several studies
INA immunohistochemistry in 1p19q codeleted and EGFR amplified gliomas Figure 7
INA immunohistochemistry in 1p19q codeleted and EGFR amplified gliomas. Representative alpha-internexin (INA) 
immunohistostaining in oligodendrogliomas with 1p19q codeletion (A, C, D) and in glioblastomas with EGFR amplification (B). 
C: the arrow shows immunopositivity in an entrapped neuron surrounded by immunopositive tumor cells.Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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isolated stem like tumor cells from glioblastoma but not
from oligodendroglioma. Such studies did not include
genetic profiles of the tumors, but data from our group
suggest indeed that the capacity of cell renewal (as
reflected by the formation of spheroids derived from the
tumor) in vitro is tightly correlated with the presence of
EGFR amplification (unpublished results). EGFR activa-
tion upregulates genes involved in neural stem cell prolif-
eration: one of these genes is ASPM (abnormal spindle-
like microcephaly associated) that promotes neuroblast
proliferation and symmetric division and is strongly
upregulated in glioblastomas. Inhibition of ASPM inhib-
its glioblastoma cell growth and neural stem cell prolifer-
ation [37].
A proneural/normal brain gene expression profile is a fac-
tor related to good prognosis and correlates with younger
age and grade III histology, with most anaplastic oli-
godendrogliomas being classified as proneural [5,28]. As
shown here, this gene expression profile can be deter-
mined by a simple, highly discriminating RT-PCR test,
and this may be useful for clinical practice. Until now, a
proneural gene expression profile has not been reported
to be associated with 1p19q codeletion. In Freije's study
the number of gliomas with 1p19q codeletion was too
small (4 out 74 patients) to address this question [28]. In
Phillips' study the genomic/transcriptomic correlation
was limited to patients with astrocytoma histology, and
this may have limited the possibility of finding an associ-
ation between 1p19q codeletion and the proneural gene
expression profile [5]. However, the authors noticed a
negative correlation between the proneural gene expres-
sion profile and EGFR amplification, similar to the nega-
tive correlation between 1p19q codeletion and EGFR
amplification [3,5]. Our study demonstrates that there is
a strong correlation between 1p19q codeletion and the
expression of proneural genes, suggesting that gliomas
with a 1p19q codeletion represent a subgroup of prone-
ural gliomas. In addition, the expression of neuronal
genes in 1p19q codeleted tumors is consistent with a pre-
vious study showing selective expression of neuronal
genes in oligodendrogliomas with 1p loss [33]. Whether
there is a link between the good prognosis of proneural
gliomas and the fact that gliomas with 1p19q codeletion
display a proneural gene expression profile remains to be
elucidated. We make the hypothesis that gliomas without
1p19q codeletion but with a gene expression profile sim-
ilar to the 1p19q codeleted gliomas might also harbor a
better prognosis.
The expression of "neuronal genes" in 1p19q codeleted
gliomas can be interpreted in different ways. As advocated
by some authors, this expression is probably due in part
to the presence of infiltrated neurons in the tumor [30].
Indeed, 1p19q codeletion has been suggested to be more
frequent in tumors with indistinct, irregular borders,
which therefore, are more likely to be contaminated with
normal brain tissue [38]. However, as shown here, this
normal brain infiltration cannot completely explain the
expression of neuronal genes by 1p19q codeleted glio-
mas. Indeed, these tumors only express a specific subset of
neuronal genes (Figure 3). In addition, if the expression of
neuronal genes was only due to infiltration of normal
brain tissue, the expression pattern of the neuronal genes
in these tumors would be similar to their expression in the
normal brain samples, which was not the case. Further-
more, we have demonstrated that alpha-internexin (INA),
a neuronal protein, was specifically expressed by 1p19q
codeleted glioma tumor cells. Thus INA expression might
be used as a simple surrogate marker of 1p19q codeletion.
This hypothesis is currently being tested in a larger series
of gliomas. Interestingly, recent ultrastructural analysis of
oligodendrogliomas has shown neuronal structures such
as synapses and neurosecretory granules [39]. Thus,
another hypothesis for the expression of neuronal genes
in 1p19q codeleted glioma tumor cells is that the cell of
origin of these tumors could be a progenitor cell giving
rise to both neurons and oligodendrocytes [40,41]. This
progenitor has less capacity of self renewal than the more
multipotent neural stem cells. This is consistent with the
fact that 1p19q codeleted oligodendroglioma fails in our
hands to form spheroids in vitro (unpublished data). In
this setting it is interesting to note that concomitant over-
expression of both BMPs and BMP antagonists, such as
the concomitant overexpression of BMP2  and  NOG
observed in 1p19q codeleted gliomas in our study, has
been demonstrated in white matter progenitor cells,
which can give rise to both oligodendrocytes and neurons
[42]. Another non-exclusive explanation for the expres-
sion of "neuronal" genes in oligodendrogliomas could
rely on the fact that some genes involved in neurogenesis
and classified as "neuronal" may also play a role in oli-
godendroglial development, e.g. ASCL1/MASH1. This
proneural gene specifies a population of telencephalic oli-
godendrocytes [43] and is also required for oligodendro-
cyte development in the spinal cord [44]. On the other
hand, Olig2 -implicated in oligodendroglial specification-
is also involved in neurogenesis: during development,
Olig2+ progenitors give rise to both motoneurons and oli-
godendrocytes in the ventral spinal cord, [45]. Consist-
ently with our results, these data, illustrating the tight
connection that exists between neurons and oligodendro-
cytes fates, bring a new light on the pathogenesis of oli-
godendrogliomas with 1p19q codeletion. Finally it is
important to remember that current WHO classification is
only based on morphological similarity between normal
cells and tumor cells, and the link between oligodendro-
cytes and oligodendrogliomas has never been demon-
strated.Molecular Cancer 2008, 7:41 http://www.molecular-cancer.com/content/7/1/41
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